An application of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in a case of hepatocellular carcinoma combined with liver cirrhosis in which leukopenia developed after chemoembolization

1991 ◽  
Vol 26 (6) ◽  
pp. 779-782 ◽  
Author(s):  
Hiroyoshi Furukawa ◽  
Tsuyoshi Hara ◽  
Kazuhiko Hoshino ◽  
Tetsushi Taniguchi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

scholarly journals A Case of Granulocyte-Colony Stimulating Factor-Producing Hepatocellular Carcinoma Confirmed by Immunohistochemistry

2010 ◽  
Vol 25 (3) ◽  
pp. 476 ◽  
Author(s):  
Satoru Joshita ◽  
Koh Nakazawa ◽  
Shoichiro Koike ◽  
Atsushi Kamijo ◽  
Kiyoshi Matsubayashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

scholarly journals Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes

2016 ◽  
Vol 7 (5) ◽  
pp. 380 ◽  
Author(s):  
Hiroaki Nagata ◽  
Shuhei Komatsu ◽  
Wataru Takaki ◽  
Tokunari Okayama ◽  
Yasunori Sawabe ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Abrupt Changes ◽  
Stimulating Factor

Granulocyte-colony-stimulating-factor-producing hepatocellular carcinoma

1999 ◽  
Vol 34 (5) ◽  
pp. 640-644 ◽  
Author(s):  
Sumie Yamamoto ◽  
Shuji Takashima ◽  
Hiroyuki Ogawa ◽  
Toshifumi Kuroda ◽  
Mitsunari Yamamoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Stimulating Factor

A Pilot Study To Evaluate the Safety, Efficacy and Effects on Liver Function of Granulocyte Colony-Stimulating Factor To Mobilize Hematopoietic Stem Cells in Patients with Liver Cirrhosis.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1698-1698
Author(s):  
Alessandro Isidori ◽  
Lucia Catani ◽  
Simona Talarico ◽  
Stefania Lorenzini ◽  
Elisabetta Loggi ◽  
...  
Keyword(s):  
Stem Cells ◽  
Liver Cirrhosis ◽  
Liver Function ◽  
Hematopoietic Stem Cells ◽  
Meld Score ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Chronic Liver Damage ◽  
Hematopoietic Stem ◽  
Stimulating Factor

Abstract In animal models hematopoietic stem cells (HSCs) and the hematopoietic cytokine granulocyte colony-stimulating factor (G-CSF) contribute to tissue regeneration after acute or chronic liver damage. In this study, we assessed whether: 1) G-CSF can be safely administered to patients with liver cirrhosis to expand and mobilize HSCs into peripheral blood; 2) G-CSF treatment affects residual liver function. Eighteen patients with a Child-Turcotte-Pugh (CTP) score < 10 and a Mayo Model for End Stage Liver Disease (MELD) score < 20 were considered eligible for the study. Increasing doses of G-CSF were administered subcutaneously for 7 consecutive days to 5 cohorts of 3 patients each, starting from 2.2 μg/kg/daily, until the achievement of the maximum-tolerated dose and/or the successful mobilization of ≥10 CD34+ cells/μl in at least 2/3 patients. G-CSF mobilizing dose was found at 15 μg/kg/day. Four additional patients were treated with the mobilizing G-CSF dose. All of them showed a successful mobilization of HSCs with a median peak value of CD34+ and CD133+ cells of 27.1(±15.5) and 15.2 (±5.1)/μl, respectively. Circulating HSCs were then collected by single volume leukapheresis and a median of 1.4(±0.73)x106 CD34+ HSCs/kg body weight were cryopreserved. G-CSF treatment induced a significant increase of hepatocyte growth factor serum level. When we analyzed stem cell subsets, we found significant mobilization of early hematopoietic (CD34+/CD38−) and endothelial (CD34+/KDR+, CD133+/KDR+) progenitors as well as CD34+/CXCR4+ cells. No severe adverse events were observed at any dosage or during leukapheresis. According to CTP and MELD score, no significant modification of liver function was observed during the treatment period and follow up (median=198 days) in both mobilizing and non-mobilizing patients. Nevertheless, in all treated patients a significant reduction of alpha-fetoprotein values was observed (p<0.001). In conclusion, the administration of G-CSF to patients with liver cirrhosis is safe, feasible and capable of mobilizing HSCs at the dosage of 15 μg/kg/day. Our study represents the first step for evaluating the role of G-CSF and mobilized HSCs to improve liver function in patients with liver cirrhosis.

Sign in / Sign up

Export Citation Format

Share Document